Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer June 14, 2024 • 12:00 a.m. Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer Uro Today, June 14, 2024“Accurately identifying patients with high-risk non-muscle invasive bladder cancer that will not respond to BCG is essential so they can receive the treatment that is best suited for them,” said UTMB’s Dr. Stephen B. Williams in this article about a newly developed histology-based test designed to predict how bladder cancer patients will respond to Bacillus Calmette-Guérin treatment.
Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer June 14, 2024 • 12:00 a.m. Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer Uro Today, June 14, 2024“Accurately identifying patients with high-risk non-muscle invasive bladder cancer that will not respond to BCG is essential so they can receive the treatment that is best suited for them,” said UTMB’s Dr. Stephen B. Williams in this article about a newly developed histology-based test designed to predict how bladder cancer patients will respond to Bacillus Calmette-Guérin treatment.